3
Announcements
Trials
Browse
Landscape
Phase
Phase 3
1
Status
Recruiting
1
Sponsor Class
INDUSTRY
1
Study Type
Interventional
1
Sponsor
Cancer Type
Thoracic
1
Conditions
Carcinoma, Non-Small-Cell Lung
8
Neoplasms
4
Neoplasm Metastasis
3
Lung Neoplasms
3
Hematologic Neoplasms
3
Neoplasms by Site
2
Neoplasms by Histologic Type
2
Lymphoproliferative Disorders
2
Lymphoma, Large-Cell, Anaplastic
2
Sexual Dysfunction, Physiological
1
Rare Tumor
1
Neuroblastoma
1
Lymphoma
1
Lung Diseases
1
Eunuchism
1
Erectile Dysfunction
1
Colorectal Neoplasms
1
Central Nervous System Neoplasms
1
Carcinoma, Renal Cell
1
Brain Neoplasms
1
Interventions
Carboplatin
5
Cisplatin
3
zipalertinib
1
zimberelimab
1
sacituzumab govitecan
1
repotrectinib
1
pembrolizumab
1
cemiplimab
1
atezolizumab
1
alectinib
1
Vital Signs
1
Tomography, Emission-Computed, Single-Photon
1
Toll-Like Receptor 1
1
Telescopes
1
Radiotherapy
1
Radiosurgery
1
Pemetrexed
1
Paclitaxel
1
Magnetic Resonance Spectroscopy
1
Etoposide
1
Drug Delivery Systems
1
Date Range
30 days
90 days
1 year
All
Options
Has results
Has announcements
Clinical Trials
1 trials
Recent
Start date
Enrollment
Recruiting
×
Lung Diseases
×
alectinib
×
Clear all
NCT06765109
2026-06-02
ALKAZAR
Nuvalent Inc.
Phase 3
Recruiting
450 enrolled